Analysts expect Teva to report Q1 2026 revenue of $3.92 billion and adjusted EPS of $0.52, while the current share price of $30.64 remains well below the $38.78 average analyst target.
The central focus for investors remains the performance of Teva's "Pivot to Growth" strategy, specifically the revenue contribution from its innovative brands led by the tardive dyskinesia treatment AUSTEDO.
Momentum in AUSTEDO is critical to offsetting a projected $1.1 billion revenue headwind from generic competition for Revlimid. Investors are also monitoring clinical pipeline milestones, particularly the anticipated FDA submission for olanzapine LAI and progress toward the company’s 30% operating margin target for 2027.